HSP90AB1 and posterior cortical atrophy: To combat severe malignancies, co-targeting of several oncoproteins has been envisioned as an effective treatment strategy due to the increased efficacy and synergistic action [138,139] Indeed, inhibition of HSP90 sensitizes PCa cells to both radiation therapy and chemotherapies [140,141].